Reliable Determination of Fetal RhD Status by &lt;b&gt;&lt;i&gt;RHD &lt;/i&gt;&lt;/b&gt;Genotyping from Maternal Plasma

Dovč-Drnovšek, Tadeja; Klemenc, Polona; Toplak, Nataša; Blejec, Tanja; Bricl, Irena; Rožman, Primož

doi:10.1159/000345682

Cited by 13 publications

(7 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In European countries, even if false-negative genotyping results are at very low rates [19,20], to further limit the risk, different strategies emerge. The attractive idea of using a foetal DNA marker in the foetal genotyping test is not so easy to apply [12].…”

Section: Discussionmentioning

confidence: 99%

Rh disease prevention: the European Perspective

Toly-Ndour

Huguet-Jacquot

Mailloux

et al. 2021

ISBT Science Series

Self Cite

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Rh disease prevention: the European Perspective

Toly-Ndour

Huguet-Jacquot

Mailloux

et al. 2021

ISBT Science Series

Self Cite

View full text Add to dashboard Cite

show abstract

“…Despite the abovementioned challenges, noninvasive fetal RHD typing is very robust and reliable, also in the first trimester, as a result of a large research endeavor that has generated technical advances and method refinement. Current assay performances are characterized by near 100% accuracies and sensitivities, surpassing a former assessed overall accuracy of 96.5% for detecting plasma cffDNA, based on a meta‐analysis of studies from 1998 to 2005 …”

Section: Prenatal Fetal Rhd Typingmentioning

confidence: 99%

“…Finning and colleagues applied a setup targeting exons 4, 5, 6, and 10, obtaining an accuracy of 100% ( n = 137) . Several assays have been reported with a similar setup, targeting several exons . For example, Minon and colleagues obtained an accuracy of 99.8% ( n = 563) .…”

Section: Prenatal Fetal Rhd Typingmentioning

confidence: 99%

“…In the case of a maternal RHD Ψ or RHD‐CE‐D s , a positive exon 5 result will indicate an RhD positive fetus . Several setups include an assay for this particular discrimination . When this technique was clinically applied, Scheffer and colleagues were able to predict the fetal RHD type correctly in eight samples carrying the RHD Ψ gene …”

Section: Prenatal Fetal Rhd Typingmentioning

confidence: 99%

See 1 more Smart Citation

Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care

Clausen

2014

Prenat Diagn

View full text Add to dashboard Cite

Incompatibility of red blood cell blood group antigens between a pregnant woman and her fetus can cause maternal immunization and, consequently, hemolytic disease of the fetus and newborn. Noninvasive prenatal testing of cell-free fetal DNA can be used to assess the risk of hemolytic disease of the fetus and newborn to fetuses of immunized women. Prediction of the fetal RhD type has been very successful and is now integrated into clinical practice to assist in the management of the pregnancies of RhD immunized women. In addition, noninvasive prediction of the fetal RhD type can be applied to guide targeted prenatal prophylaxis, thus avoiding unnecessary exposure to anti-D in pregnant women. The analytical aspect of noninvasive fetal RHD typing is very robust and accurate, and its routine utilization has demonstrated high sensitivities for fetal RHD detection. A high compliance with administering anti-D is essential for obtaining a clinical effect. Noninvasive fetal typing of RHC/c, RHE/e, and KEL may become more widely used in the future.

show abstract

“…Significant progress in prenatal care strategies for the fetus with RhD has occurred during the last few decades. Cell-free fetal DNA (cffDNA) discovered from plasma of pregnant women by Lo et al in 1997 has been used for the noninvasive detection of fetal RhD status [ 7 – 9 ], which has the potential to avoid antenatal anti-RhD prophylaxis in RhD negative women [ 5 , 10 – 12 ]. Many obstetricians accept fetal RhD status detection using circulating cffDNA from maternal plasma or serum.…”

Section: Introductionmentioning

confidence: 99%

A new biosensor for noninvasive determination of fetal RHD status in maternal blood of RhD negative pregnant women

Yenilmez¹,

Kökbaş²,

Kartlaşmış³

et al. 2018

PLoS ONE

View full text Add to dashboard Cite

Prenatal detection of the fetal RHD status can be useful in the management of RhD incompatibility to identify fetuses at risk of hemolytic disease. Hemolytic disease causes morbidity and mortality of the fetus in the neonatal period. The routine use of antenatal and postnatal anti-D prophylaxis has reduced the incidence of hemolytic disease of the fetus and newborn. This study describe the detection of fetal RhD antigens in blood of RhD negative pregnant women using a nanopolymer coated electrochemical biosensor for medical diagnosis. Cell free fetal DNA in maternal plasma was also used to genotyping fetal RHD status using multiplex real-time PCR. Twenty-six RhD negative pregnant women in different gestational ages were included in the study. RhD positive fetal antibodies detected with a developed biosensor in maternal blood of RhD negative mothers. The electrochemical measurements were performed on a PalmSens potentiostat, and corundum ceramic based screen printed gold electrode combined with the reference Ag/AgCl electrode, and the auxiliary Au/Pd (98/2%) electrode. Fetal RHD genotyping performed using fluorescence-based multiplex real-time PCR exons 5 and 7 of the RHD gene. The fetal RHD status of 26 RhD negative cases were detected 21 as RhD positive and 5 as RhD negative with electrochemical biosensor. Fetal RHD status confirmed with extracted fetal DNA in maternal plasma using multiplex real-time PCR RHD genotyping and by serological test after delivery. The new method for fetal RhD detection in early pregnancy is useful and can be carry out rapidly in clinical diagnosis. Using automated biosensors are reproducible, quick and results can be generated within a few minutes compared to noninvasive fetal RHD genotyping from maternal plasma with real-time PCR-based techniques. We suggest the biosensor techniques could become an alternative part of fetal RHD genotyping from maternal plasma as a prenatal screening in the management of RhD incompatibility.

show abstract

Reliable Determination of Fetal RhD Status by <b><i>RHD </i></b>Genotyping from Maternal Plasma

Cited by 13 publications

References 34 publications

Rh disease prevention: the European Perspective

Rh disease prevention: the European Perspective

Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care

A new biosensor for noninvasive determination of fetal RHD status in maternal blood of RhD negative pregnant women

Contact Info

Product

Resources

About